Dr. Hallam brings broad pharmaceutical industry expertise to his role with Leading BioSciences, having leadership experience in virtually every stage of pre-clinical research, clinical development and regulatory affairs. Prior to joining Leading BioSciences, he served as director of therapeutic programs and head of new product development for Mesoblast Inc., directing commercialization strategy and product development for the company’s adult stem cell products. He previously served in the San Francisco office of C1 Consulting, assisting pharmaceutical companies launch and commercialize new products, and as medical director at Saatchi & Saatchi Healthcare in New York. Under his leadership at Saatchi & Saatchi, the healthcare marketing team was named “Best Large Marketing Team of 2010” by Medical Marketing and Media Magazine. Past experience also includes leading the pharmacology group at Helicon Therapeutics, where he directed research operations at four U.S. locations and managed global CRO operations. Over the course of his career, he has successfully advanced eight drugs from pre-clinical research to Phase 2 trials, designing clinical studies to maximize data for regulatory approval, business development and marketing. He has served as a consultant and advisor to some of the world’s leading healthcare companies, including Roche/Genentech, Pfizer, Sanofi, Astra-Zeneca, Bausch & Lomb, Somaxon, CogMed, Pearson, Dart Neuroscience, and Ogilvy CommonHealth.
Dr. Hallam is a former Howard Hughes Medical Institute Research fellow. He received his Ph.D. in neuroscience from University California, Davis, earned a master’s degree in business administration from the University of Southern California, and holds a bachelor’s degree in biology from the University of Illinois at Urbana-Champaign.
What is Thomas Hallam's net worth?
The estimated net worth of Thomas Hallam is at least $6,718.25 as of August 16th, 2022. Dr. Hallam owns 3,839 shares of Palisade Bio stock worth more than $6,718 as of December 22nd. This net worth approximation does not reflect any other assets that Dr. Hallam may own. Learn More about Thomas Hallam's net worth.
How do I contact Thomas Hallam?
Has Thomas Hallam been buying or selling shares of Palisade Bio?
Thomas Hallam has not been actively trading shares of Palisade Bio within the last three months. Most recently, on Tuesday, August 16th, Thomas Hallam bought 2,666 shares of Palisade Bio stock. The stock was acquired at an average cost of $3.75 per share, with a total value of $9,997.50. Following the completion of the transaction, the chief executive officer now directly owns 3,839 shares of the company's stock, valued at $14,396.25. Learn More on Thomas Hallam's trading history.
Who are Palisade Bio's active insiders?
Are insiders buying or selling shares of Palisade Bio?
During the last year, Palisade Bio insiders bought shares 3 times. They purchased a total of 2,666 shares worth more than $15,664.00. The most recent insider tranaction occured on May, 28th when Director Donald Allen Williams bought 1,000 shares worth more than $4,860.00. Insiders at Palisade Bio own 3.3% of the company.
Learn More about insider trades at Palisade Bio. Information on this page was last updated on 5/28/2024.
